ASND News & Events

Reports Q1 revenue EUR 246.6M, consensus EUR 269.64M. Reports Q1 Yorvipath revenue EUR 197M. Reports Q1 Skytrofa revenue EUR 44M. "The FDA approval of YUVIWEL, our third consecutive TransCon product, and the robust patient uptake for YORVIPATH are cementing our position as a leading global biopharma," said CEO Jan Mikkelsen.

Ascendis Pharma announced the commencement of trading of its ordinary shares on The Nasdaq Global Select Market, replacing the listing of American Depositary Shares.